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 Summary 
Introduction 
Skin cancer is the commonest malignancy worldwide, often occurring on the face. 
Both the condition and treatment can lead to scarring and facial disfigurement, 
affecting a patient’s health-related quality of life (HRQoL), which can be measured 
using patient-reported outcome measures (PROMs). This systematic review identifies 
PROMs for facial skin cancer and appraises their methodological quality and 
psychometric properties using up-to-date methods.  
 
Methods 
MEDLINE, EMBASE, PsychINFO, Cochrane and CINAHL were systematically 
searched in accordance with PRISMA guidelines, identifying all PROMs designed for 
or validated in facial skin cancer. Methodological quality and evidence of 
psychometric properties were assessed using the COnsensus-based Standards for the 
Selection of Health Measurement INstruments (COSMIN) checklist and criteria 
proposed by Terwee et al. A best evidence synthesis and assessment of instrument 
focus on post-resection reconstruction was also performed.     
 
Results 
Twenty-four studies on 11 PROMs were included. Methodological quality and 
psychometric evidence was variable, with the Patient Outcome of Surgery – 
Head/Neck (POS-H/N), Skin Cancer Index (SCI), Skin Cancer Quality of Life Impact 
Tool (SCQLIT) and Essers et al demonstrating the greatest level of validation. None 
scored well in their relevance to post-skin cancer reconstruction of the face.  
 Discussion 
This systematic review critically appraises PROMs for facial skin cancer using 
internationally accepted criteria. The identified PROMs demonstrate a variation in the 
quality of validation performed, with a need to improve this across all PROMs in the 
field. Only through improving the quality of PROMs available and their focus on the 
post-treatment aesthetic and functional outcome will we be able to truly appreciate the 
concerns of our patients’ and improve the management of facial skin cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Bulleted Summary 
1. What is already known about this topic? 
 Patient-reported outcome measures (PROMs) are important in both research 
and daily clinical practice. This is especially true in facial skin cancer, where both the 
condition and the resulting aesthetic outcome of treatment are important. PROMs for 
facial skin cancer exist, however their validity against the contemporary international 
consensus have yet to be reported. The relevance of these PROMs to patients’ views 
of treatment outcomes is yet to be investigated. 
 
2. What does this study add? 
 This systematic review provides a comprehensive assessment of the validity of 
those PROMs used for facial skin cancer using current best practice assessment tools, 
helping clinicians and researchers to select the most appropriate PROM to use. Each 
PROM is also assessed for relevance to the post-treatment aesthetic outcome, with a 
recommendation that further validated items are required to adequately assess this 
important area of skin cancer treatment. 
 
 
 
 
 
 
 
 
 Introduction 
 Skin cancer is the commonest malignancy worldwide(1), affecting 1 in 5 
Americans during their lifetime(2). The incidence of non-melanoma skin cancers 
(NMSC) in England is 98.85/100,000 person-years and predominantly affects the 
face(3,4). 70,000 new diagnoses of NMSC were made in the United Kingdom in 
2013(5), presenting a significant and growing health burden. Although skin cancer 
mortality is low, particularly for NMSC(5,6), the diagnosis is often psychologically 
damaging, including anxiety over the cancer diagnosis(7) and concerns over visible 
scarring, especially on the face(8), affecting health-related quality of life (HRQoL).  
 HRQoL has been given a number of definitions(9), but broadly represents an 
individual’s perception of the effects of an illness and/or treatment on physical, 
psychological and social aspects of their life(10). One method for assessing HRQoL is 
the use of patient-reported outcome measures (PROMs). PROMs are standardised, 
validated questionnaires that are completed by patients and capture one or more 
aspects of their health and wellbeing(11,12). They are considered by the UK 
Department of Health as the current best method for quantifying a patient’s clinical 
experience. Currently only four conditions have routine PROM data collected at a 
national level in the UK(12), although PROM data collection in many different cancer 
registries and dermatological trials is now commonplace(13,14).  
 Previous reviews have demonstrated a number of PROMs used in the 
assessment of patients with both skin cancer generally(15,16) and facial skin 
cancer(17). However, none have used current ‘gold-standard’ methodology for 
assessing the methodological quality of included studies, or the quality of those 
PROMs’ measurement properties. Furthermore, given the burden associated with 
cosmetic outcomes in post-skin cancer facial reconstruction, no review has yet 
assessed available PROMs for their focus on this. In an era of core outcome sets 
(COS)(18,19), where agreed upon minimum sets of outcomes when reporting 
research are expected, it is important that PROMs are appraised for their validity. If 
validation, or relevant items for the condition of interest are lacking, it is important 
that this is identified and rectified before inclusion in a COS.    
The objectives of this systematic review are therefore to: (1) identify PROMs 
that have been designed for and/or validated in patients with facial skin cancer, (2) 
assess the methodological quality of the included studies, (3) assess the psychometric 
properties of those identified PROMs, (4) to make an assessment of the focus of each 
PROM on the reconstructive aspect of patient care and (5) to make recommendations 
that could lead to the development of a facial skin cancer COS.  
 
Methods 
Search Strategy and Selection Criteria 
 A systematic review protocol was developed in accordance with the Preferred 
Reporting for Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-
P)(20,21) and registered with PROSPERO (CRD42016043181).  
 The search strategy was constructed in line with PRISMA guidelines(22), the 
Cochrane handbook(23) and guidance from Terwee et al(24). To identify all papers 
that discussed some aspect of PROM development or validation for facial skin cancer, 
three separate constructs were explored; target condition, target body area and 
measurement instrument (e.g. PROM). Key words and MeSH terms were selected 
where available and searches were performed in; MEDLINE (Ovid), Embase (Ovid), 
PyschINFO (Ovid), Cochrane and CINAHL (EBSCO). An example search strategy 
can be seen in Supplementary Figure 1. Grey literature and reference lists were also 
searched using Google, Google Scholar and known PROMs based websites. Searches 
were performed by two independent researches (TD and HS) on the same day in 
August 2016, with results uploaded to the reference management software package, 
EndNote® Version X7 (Clarivate Analytics). The search strategy was re-run prior to 
submission in January 2018 to identify any further studies that matched the inclusion 
criteria. Duplicates were removed using the functionality in EndNote®, with all 
references transferred to the online programme Covidence (www.covidence.org) for 
title and abstract screening. References were screened by two independent reviewers 
(TD and HS) according to the inclusion and exclusion criteria (Table 1), with all 
remaining articles downloaded in full-text format and re-screened. Discrepancies 
were discussed between the two reviewers with a third reviewer (HH) consulted if 
required.    
 
Assessment of the Methodological Quality of included studies 
 The methodological quality of included studies was assessed using the 
COnsenus-based Standards for the Selection of Health Measurement INstruments 
(COSMIN)(25,26). The COSMIN checklist contains 9 main sections each assessing a 
different measurement property: internal consistency, reliability, measurement error, 
content validity, construct validity (structural validity and hypothesis testing), cross-
cultural validity, criterion validity and responsiveness. An updated checklist with a 4-
category rating scale (4-excellent, 3-good, 2-fair, 1-poor) was used(27). Each paper 
included in the review was compared against the 98-items in the checklist, and for 
those where evidence was presented in the paper, a score on the 4-category scale was 
given. One is only able to assess criterion validity where the PROM in question was 
compared to a longer version. Any paper describing criterion validity but not actually 
assessing against a ‘gold standard’ or long-version was not assessed for criterion 
validity. The final rating for methodological quality in any given area of assessment is 
considered to be the lowest score (i.e. if a property such as internal consistency is 
scored ‘excellent’ in one question, but ‘poor’ in another, the methodological quality 
for that property is considered to be ‘poor’).   
 The COSMIN checklist has good inter-rater agreement and reliability(28), 
however to account for bias and subjectivity when rating studies it is considered good 
practice to compare results between two independent reviewers. A randomly-selected 
sample of 30% of the included studies were assessed by two reviewers (TD and SH) 
and compared using intraclass coefficient (ICC)(29), Cohen’s Kappa(30) and 
percentage agreement. If agreement was low in this sample, all included studies 
would be doubly assessed.  
 
Assessment of Psychometric Properties  
 The psychometric quality of each PROM was assessed using criteria 
developed by Terwee et al(31) and updated in 2016(32). Supplementary figure 2 
describes the measurement properties that are assessed according to these criteria. 
Each criterion is rated as criteria met (+), criteria not met (-), or not all information 
present (?). 
 
Data analysis and best evidence synthesis  
 Data were collated in Excel for Mac (V14.5.7) and presented as tables and 
narrative synthesis. Inter-rater reliability statistics were calculated for the COSMIN 
analysis using the Statistical Package for the Social Sciences (SPSS) software V.22 
(IBM Corp., New York, USA).  
 A best evidence synthesis was performed by applying the levels of evidence 
summary as described by Furlan et al(33) to the combined results of the COSMIN and 
Terwee et al assessments. The Outcome Measures in Rheumatology (OMERACT) 
criteria were then used to categorise each instrument into A) instrument meets all 
requirements and is recommended for use, B) instrument meets two or more required 
items and therefore has potential for use, C) instrument has low quality in at least one 
area and is not recommended for use and D) instrument has almost no 
validatation(34). This method has previously been used by Gerbens et al in the 
dermatology literature(35).     
 
Assessment of Reconstructive Relevance 
 The focus of each PROM on reconstruction post-skin cancer has never been 
assessed before and therefore there is no framework to work from. We therefore 
performed a subjective assessment of the included questions based on specialist 
knowledge of the topic area by the authors. As a reconstructive PROM was not the 
aim of the original scale developers we have performed this assessment separately 
and did not let this influence the COSMIN analysis when judging content validity.  
 
Results 
 4886 articles were independently reviewed by two reviewers. With the 
addition of articles identified during reference searching a total of 24 studies were 
finally included (Figure 1)(7,36-58). Of those articles included, 11 different PROMs 
were identified: 2 generic PROMs (SF-36 and FACT-G) and 9 skin cancer-specific 
(FACT-M, POS-H/N, SCI, SCQoL, aBCCdex, SCQOLIT, FACE-Q, DLQI, Essers et 
al). As per the inclusion criteria, all PROMs included demonstrated some aspect of 
validation in the facial skin cancer population. A summary of identified PROMs and 
included papers describing aspects of design or validation are presented in Table 2. A 
more detailed assessment of each instrument is presented in Supplementary Figure 3.   
 
Methodological quality of those included studies 
 Raw individual category scores for each PROM are presented in Table 3. Of 
the 11 PROMs included, there was a range of methodological quality, with only one 
paper scoring in all 8 of the COSMIN categories (FACT-M). The spread of ratings 
between the 4 categories (excellent, good, fair and poor) was relatively even, with 
28% being ‘excellent’, 18% ‘good’, 14% ‘fair’ and 40% ‘poor’. The content validity 
for all bar 1 condition-specific PROMs (Essers et al) demonstrated ‘excellent’ 
methodology. Of the other categories, internal consistency and structural validity are 
the next two most commonly reported on and appropriately investigated areas of 
PROM development and validation in the identified studies.  
 ICC of 0.844 (0.796 – 0.88), Kappa of 0.648 (p < 0.005) and a percentage 
agreement of 97.84% was observed between the two reviewers, demonstrating good 
agreement.  
 
Psychometric properties of included patient-reported outcome measures 
 The results of the psychometric evaluation are shown in Table 4. Of the 11 
PROMs assessed, none scored positively in all domains. The PROMs with the lowest 
scoring psychometric measurement properties as assessed using criteria produced by 
Terwee et al were SF-36, FACT-G and FACE-Q skin cancer module. The FACE-Q 
skin cancer module was only described in outline in one paper(54), hence the scores 
noted in Table 4.  
 Content validity and internal consistency are the two most commonly reported 
on and well-designed aspects of PROMs validation papers. Seven out of 9 condition-
specific PROMs showed ‘appropriate assessment of content validity’, demonstrating 
appropriate use of commonly used methods to generate items specific to the patient 
group(59). Good internal consistency, as demonstrated as having a Cronbach’s alpha 
of 0.70 – 0.95, was shown in 8 of the 9 condition-specific PROMs.  
 The presentation of data in the included studies required to assess the other 
criteria of Terwee et al was, however, more sporadic. Overall, the SCI showed the 
greatest number of positive ratings across all domains.  
 
Best evidence synthesis 
 A summary of the best evidence synthesis using the method outlined can be 
seen in Table 5. Using the OMERACT filter no PROMs met the criteria for an ‘A’ 
graded PROM, 4 PROMs were considered to be a ‘B’ graded PROM, 4 were ‘C’ 
grade PROMs, 2 were ‘D’ grade PROMs and 1 was un-gradable.  
 
Focus on reconstructive aspects in each questionnaire 
 An assessment of the questions included in each questionnaire was made for 
their relevance to and focus on the reconstructive aspects and cosmesis of facial skin 
cancer. A summary of the questions that hold some relevance to reconstruction for 
each PROM is shown in Table 6. 
 
 
  
Discussion 
 This systematic review has been designed to identify all PROMs that are 
validated for use in patients with facial skin cancer. At a time when the use of PROMs 
is being encouraged in both research and clinical use, it is important that only those 
PROMs that show evidence of validation are used. In the ideal world these would be 
validated in the exact population in which they were being implemented, however in 
practice this is often too time-consuming and expensive. Previous systematic reviews 
on this topic(16,17) have demonstrated many similar PROMs to this review, however 
we have assessed the methodological quality of these studies using internationally 
accepted criteria to minimise the risk of bias. This was performed using the COSMIN 
checklist, the current ‘gold standard’ for appraising and reporting the methodological 
rigour of studies reporting on instrument design and validation(26). It is now routinely 
accepted across the systematic review literature and has been used extensively in 
orthopaedics(60), paediatrics(61), neurology(62) and dermatology(35). A further 
update to the COSMIN methodology has been published, although this was after this 
review was performed(63). We also assessed the quality of the psychometric 
properties of the included PROMs using Terwee et al(32)’s criteria and performed a 
best evidence synthesis.  
 Of the two generic instruments identified, SF-36 and FACT-G, only 
rudimentary validation was provided in 1 paper(43). Both instruments are well 
established in the literature for their general use, however due to poor evidence of 
validation in the facial skin cancer population their use in this setting is difficult to 
recommend. This is mainly due to the instruments initially being designed for a 
different population to the one studied here and therefore they lack face and content 
validity. For example, the issues affecting a facial skin cancer population are likely to 
be very different to those affecting the population groups used to design the SF-36. 
There was a range of quality with respect to design and validation across the 9 
condition-specific PROMs identified. After removing FACE-Q from the analysis due 
to only very preliminary work being available, of the remaining 8 condition-specific 
PROMs internal consistency was measured in 7, with a range of ratings seen. 
Reliability was less frequently reported, but in a similar manner to internal 
consistency there was a range of ratings from poor to good. Measurement error and 
criterion validity were the most poorly reported, with only 3 PROMs demonstrating 
evidence of measurement error assessment. This may be due to the need for the 
instrument to be administered twice in order to calculate measurement error, 
increasing the time for data collection(59). Unfortunately, measurement error is an 
important concept required to design high quality prospective studies using these 
instruments. Evidence for content validity was excellent in all but 1 condition-specific 
PROM (Essers et al), with all condition-specific PROMs attempting to include 
representative patients in their design and validation. Structural validity and 
hypothesis testing were broadly done well. Criterion validity was poorly reported and 
in those reporting it, poorly done. This is due largely to the lack of a ‘gold standard’ 
comparator instrument. Finally, responsiveness was reported in 6 of the condition-
specific PROMs. Ratings were either poor or fair and in a similar manner to 
measurement error, the need for at least two administrations in a longitudinal design 
may be why this is being poorly performed.   
 Combining the results of the COSMIN and Terwee et al analysis into a best 
evidence synthesis identified 4 PROMs that are currently the most appropriate for 
inclusion in a COS for facial skin cancer: POS-H/N, SCI, SCQOLIT and Essers et al. 
All of these still have deficiencies in their validation however (Table 5) and further 
studies are advised. Furthermore, the FACE-Q skin cancer module has the potential to 
be a well-designed and validated instrument, but further studies are awaited.    
 This is the first systematic review on the subject to assess each PROM for 
their focus on the post-resection reconstruction of facial skin cancer. The results show 
that this is poorly addressed, even in PROMs designed specifically for facial skin 
cancer. Questions relating to the degree of scarring, how noticeable it is, physical 
symptoms such as pain and itch and psychological concerns all featured, but no single 
instrument adequately addressed this area. This is an important finding. In an era 
where skin cancer is treatable the long term sequelae of the treatment given is 
important, especially where this results in visible and potentially disfiguring scarring 
on the face. The only way in which the medical community will be able to improve 
the treatment offered is by asking patients what they think, through the medium of 
PROMs. It is therefore important that PROMs exist which include relevant and valid 
items relating to issues such as the reconstruction if they are to be included in a facial 
skin cancer COS. A COS for basal cell carcinomas is already in creation(64) and the 
CSG-COUSIN group(65) plan many more in the dermatology world. We therefore 
hope and implore that these take into account areas such as aesthetic and functional 
outcomes of reconstructive surgery.    
 The use of the COSMIN checklist is a strength of this study, however despite 
being validated and well accepted in the literature, there are limitations associated 
with it. Firstly, scoring of each item in the checklist is reliant on author judgment and 
therefore can be subjective. Secondly, the checklist is extensive and while this means 
it is considered to be the ‘gold-standard’ it is potentially difficult for the non-health 
outcome specialist to use.  
 In this systematic review we tried to control for inter-rater reliability issues by 
two independent reviewers assessing a randomly selected selection of papers. An 
intra-class coefficient (ICC) score of 0.844 (considered ‘good’ by Koo and Li(66)), 
Kappa statistic of 0.648 (p < 0.005) (‘moderate agreement’(67)) and percentage 
agreement of 97.84% validated our inter-rater reliability and therefore COSMIN 
scores. While this assessment provides some reassurance when using COSMIN, we 
appreciate that it is feasible that another review team may score items differently.    
 Another strength of this systematic review is the use of a validated and highly 
sensitive search strategy, using guidance from the Cochrane group(23) and Terwee et 
al(24). We used a broad search strategy to identify all relevant studies demonstrating 
some aspect of design or validation of a PROM for facial skin cancer. However, this 
could also be a limitation in that we only included those studies that demonstrated 
aspects of design or validation. Studies that used a PROM in the facial skin cancer 
population but did not assess validation were excluded, potentially missing PROMs, 
which if they were validated, may be useful in this population group.  
 
Conclusion 
 This systematic review has identified a number of different PROMs relevant 
to the facial skin cancer population. The identified PROMs demonstrated variable 
psychometric validation and all poorly addressed the reconstructive aspects of facial 
skin cancer. While POS-H/N, SCI, SCQOLIT and Essers et al all show potential, 
further validation work is required before they could be confidently included in a 
COS. 
 In order to move forward and improve our understanding of patients’ views on 
facial skin cancer and the difference between treatment options, it is important that 
these deficiencies in validation studies are addressed. Furthermore, additional items, 
either as an addition to a current PROM or included in an entirely new PROM, are 
required to specifically address the reconstruction and aesthetic outcomes of facial 
skin cancer. It is hoped that in time the tools will exist to confidently assess our 
patients’ views on their facial skin cancer and treatment outcomes, reducing the 
psychological and social burden associated with this disease.  
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Table 1 – Inclusion and exclusion criteria used when screening identified studies.  
 
 
 
Inclusion criteria 1) Head and neck skin cancer population  
2) Papers discussing some aspect of 
PROM development or validation 
3) English only articles 
 
Exclusion criteria 1) Questionnaires not developed or 
validated in patients with head and neck 
skin cancer 
2) Oropharyngeal head and neck cancer 
population 
3) Questionnaires developed to assess 
nodal or distant metastatic disease 
4) General oncology questionnaires 
unless specifically validated in a head and 
neck skin cancer population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 2 – Summary of patient-reported outcome measures (PROMs) and 
corresponding papers identified using the inclusion and exclusion criteria of this 
systematic review. The number of items in each questionnaire and domains assessed 
are documented. 
 
 
 
PROM Papers included Generic or 
condition-
specific 
Number 
of items 
Domains 
SF-36 Rhee et al, 2003(43) Generic 36  Vitality 
 Physical functioning  
 Bodily pain 
 General health perception 
 Physical role functioning 
 Emotional role functioning  
 Social role functioning 
 Mental health 
FACT-G Rhee et al, 2003(43) Generic 27  Physical  
 Social/family 
 Emotional 
 Functional well-being 
FACT-M Cormier et al, 2005(37) 
Cormier et al, 2008(38) 
Askew et al, 2009(39) 
Swartz et al, 2012(40) 
Winstanley et al, 
2013(41) 
Condition-
specific 
24 (in 
FACT-M 
subscale) 
18 in 
reduced 
version 
 Physical well-being 
 Emotional well-being 
 Social well-being 
POS-H/N Cano et al, 2006(42) Condition-
specific 
15 (6 
pre-
operative
ly and 9 
post-
operative
ly) 
 Psychological functioning and 
cosmetic appearance 
 Satisfaction 
 
SCI Rhee et al, 2005(36) 
Matthews et al, 
2006(44) 
Rhee et al, 2006(45) 
Rhee et al, 2007(46) 
de Troya-Martin et al, 
2015(47) 
Korner et al, 2016(7) 
Condition-
specific 
15  Emotion 
 Social 
 Appearance 
 
SCQoL Vinding et al, 2013(48) 
Vinding et al, 2014(49) 
Condition-
specific 
9  Function 
 Emotions 
 Control 
 
aBCCdex Mathias et al, 2014(50) 
Mathias et al, 2015(51) 
Condition-
specific 
26  Worry about future lesions 
 Mental health 
 Social/Relationships 
 Lesion symptoms 
 Life impact 
 
SCQOLIT Burdon-Jones et al, 
2010(52) 
Burdon-Jones et al, 
2012(53) 
Condition-
specific 
10  Psychosocial 
 Physical 
 
FACE-Q Lee et al, 2015(54) Condition-
specific 
N/A N/A 
DLQI Finlay et al, 1994(55) 
Blackford et al, 
1996(56) 
Generic 
skin PROM 
10  Symptoms and feelings 
 Daily activities 
 Leisure 
 Work and school 
 Personal relationships 
 Treatment 
 
Esser et al Essers et al, 2006(57) 
Essers et al, 2007(58) 
Condition-
specific 
22  Worrying about facial health 
 Susceptibility for facial BCC 
 Fear of developing a new BCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 – Individual category scores for each study for all included patient-reported outcome measures (PROMs) as assessed by the COSMIN 4-
point scale. Each domain is made up of a number of questions as part of the COSMIN checklist, with the lowest scoring category representing 
the overall methodological quality for that domain in the paper assessed.  
 
PROM Paper Internal 
consistency 
Reliability Measurement 
error 
Content 
validity 
Structural 
validity 
Hypotheses 
testing 
Criterion 
validity 
Responsiveness 
SF-36 Rhee et al, 
2003 
Poor -- -- -- -- -- -- -- 
 
FACT-G Rhee et al, 
2003 
Poor -- -- -- -- -- -- -- 
 
FACT-M Cormier et 
al, 2005 
-- -- -- Excellent -- -- -- -- 
Cormier et 
al, 2008 
Poor Poor Poor Poor Poor Good Poor Fair 
Winstanley 
et al, 2012 
Excellent -- -- -- Excellent -- -- -- 
Swartz et 
al, 2012 
Excellent Poor -- -- Excellent -- -- -- 
 
POS-
Head/Neck 
Cano et al, 
2005 
Excellent Poor Excellent Excellent -- Poor -- Poor 
 
FSCI/SCI Rhee et al, 
2005 
Poor -- -- Excellent -- -- -- -- 
Matthews 
et al, 2006 
Poor Poor -- Excellent Poor -- -- -- 
Rhee et al, 
2006 
Good -- -- -- -- Good -- -- 
Rhee et al, 
2007 
-- -- -- -- -- -- -- Fair 
de Troya-
Martin, 
2012 
Good Good -- Excellent Good Poor -- -- 
 
SCQoL Vinding et 
al, 2013 
*IRT 
Poor -- -- Excellent Excellent Fair -- -- 
Vinding et 
al, 2014 
-- -- -- -- -- Fair -- Fair 
 
aBCCdex Mathias et 
al, 2014 
-- -- -- Excellent -- -- -- -- 
Mathias et 
al, 2015 
Good Good -- -- Good Fair -- Poor 
 
SCQOLIT Burdon-
Jones et al, 
2009 
-- -- -- Excellent -- -- -- -- 
Burdon-
Jones et al, 
2012 
Good Good Poor Excellent Poor Good -- Poor 
 FACE-Q 
Skin 
cancer 
module 
Lee et al, 
2015 
-- -- -- -- -- -- -- -- 
 
DLQI Finlay et 
al, 1993 
-- Fair -- Excellent Poor -- -- -- 
Blackford 
et al, 1996 
-- -- -- -- -- Poor -- -- 
 
Essers et al Essers et 
al, 2006 
and 2007 
Good -- -- Fair Fair -- -- -- 
 
All domains are scored according to the COSMIN checklist with 4-point scale(27). Potential categories include; excellent, good, fair and poor.  
(--) indicates domains not measured in a study. * refers to the use of Item Response Theory, rather than Classical Test Theory. 
 
 
 
 
 
Table 4 - Individual category scores assessing psychometric properties for each study for all included patient-reported outcome measures 
(PROMs) as developed by Terwee et al(31,32).  
 
PROM Paper Internal 
consistency 
Reliability Measurement 
error 
Content 
validity 
Structural 
validity 
Hypotheses 
testing 
Criterion 
validity 
Responsiveness 
SF-36 Rhee et al, 
2003 
-        
 
FACT-G Rhee et al, 
2003 
-        
 
FACT-M Cormier et 
al, 2005 
   +     
Cormier et 
al, 2008 
+   +  +  - 
Winstanley 
et al, 2012 
+    +    
Swartz et 
al, 2012 
-        
 
POS-
Head/Neck 
Cano et al, 
2005 
+ +  +  +  + 
 
FSCI/SCI Rhee et al, 
2005 
        
Matthews 
et al, 2006 
+   + -    
Rhee et al, 
2006 
+     +   
Rhee et al, 
2007 
       + 
de Troya-
Martin, 
2012 
- +  +  +   
 
SCQoL Vinding et 
al, 2013 
*IRT 
+   + + -  - 
Vinding et 
al, 2014 
     -  - 
 
aBCCdex Mathias et 
al, 2014 
   +     
Mathias et 
al, 2015 
+ -  +  +  + 
 
SCQOLIT Burdon-
Jones et al, 
2009 
   +     
Burdon-
Jones et al, 
2012 
+ +  +  +   
 FACE-Q 
Skin 
cancer 
module 
Lee et al, 
2015 
        
 
DLQI Finlay et 
al, 1993 
   +     
Blackford 
et al, 1996 
     +   
 
Essers et al Essers et 
al, 2006 
and 2007 
+   +     
 
Each criterion is assessed as either; positive rating (+), negative rating (-), or indeterminate rating (?). (Blank) indicates domains not measured or 
where no evidence is presented. 
 
 
 
 
 
Table 5 – Best evidence synthesis and grading according to the OMERACT filter 
 
PROM Internal 
consistency 
Reliability Measurement 
error 
Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Criterion 
validity 
Responsiveness OMERACT 
recommendation 
SF-36 ?        D 
FACT-G ?        D 
FACT-M ± ? ? ± ± ++ ? - C 
POS-H/N +++ ? ± +++  ?  ? B 
SCI ± ±  +++ ± ±  + B 
SCQoL ?   +++ +++ -  - C 
aBCCdex ++ --  +++ ± +  ? C 
SCQOLIT ++ ++ ? +++ ? ++  ? B 
FACE-Q         N/A 
DLQI  -  +++ ? ?   C 
Essers et al ++   + ±    B 
 
 
Positive rating for measurement property (+++ consistent findings in multiple studies of good methodological quality or one study of excellent 
quality / ++ consistent findings in multiple studies of fair methodological quality or one good study / + one study of fair methodological quality).   
Negative rating for measurement property (--- consistent findings in multiple studies of good methodological quality or one study of excellent 
quality / -- consistent findings in multiple studies of fair methodological quality or one good study / - one study of fair methodological quality). ? 
indicated indeterminate due to poor quality study. ± indicates conflicting evidence.  
OMERACT filter using categories of A, B, C, D as discussed in the methods. Category of B/C where a PROM has aspects of category B and C. 
 Table 6 – Assessment of each questionnaire for a focus on questions relating to 
reconstruction and the post-treatment aesthetics 
 
PROM Questions with a focus relevant to reconstruction Global 
summary of 
focus on 
reconstruction 
SF-36 No questions relevant to reconstruction Absent  
FACT-G No questions relevant to reconstruction Absent 
FACT-M Four items show some relevance 
- I feel numbness at my surgical site 
- I have pain at my melanoma site or surgical scar 
- I worry about the appearance of surgical scars 
- I have swelling as a result of surgery 
Poor 
POS-H/N Post-surgical questionnaire attempts to address 
aspects of the operation and outcomes 
- are the results of the operation on your head/neck 
skin growths – better/about/worse than expected? 
- if a friend has a similar head/neck skin growths that 
you had before your operation would you recommend 
the same operation you had? 
Average 
SCI Two items relating to scarring  
- worried about how large the scar will be? 
- thought about how noticeable the scar will be to 
others? 
Average 
SCQoL No focus on the treatment or reconstructive aspect. 
One question with a vague reference to aesthetics 
- during the past week, I have used such things as 
make-up or clothing to hide my skin cancer from 
others 
Poor 
aBCCdex Items relevant to appearance  
 - your appearance changing due to surgery or 
procedures 
Three items relating to the lesion 
 - bleeding from lesion(s) 
- oozing or pus from lesions(s) 
- sensitive/tender skin around lesion(s) 
However, no questions with a focus on the 
reconstruction 
Poor 
SCQOLIT One item relating to disfigurement and one relating to 
discomfort following the treatment  
- over the last week, how much have you been 
bothered about any disfigurement or scarring, in 
respect to your skin cancer or its treatment? 
- over the last week, how much skin discomfort or 
inconvenience have you experienced, in respect to 
your skin cancer or its treatment? 
Poor/Average 
FACE-Q No specific questionnaire items have yet to be 
published but one of the aims of the new skin cancer 
module is to address areas around facial aesthetics 
Absent 
DLQI No questions relevant to reconstruction Absent  
Esser et al No questions relevant to reconstruction Absent 
 
 
 
 
 
 
 
  
Figure Legend: 
 
Figure 1 – PRISMA flow diagram demonstrating the identification and screening of 
studies for inclusion
 
